Neurocrine Biosciences, Inc.

Good day, everyone, and welcome to Neurocrine Biosciences Report's first quarter 2025 results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. Please note, today's call will be recorded, and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Todd Tushla. Vice President of Investor Relations. Please go ahead.

Thank you, and happy Cinco de Mayo to everyone. Welcome to Nurocrine Biosciences first quarter 2025 earnings call. With me today are Kyle Gaino, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Eric Benevich, Chief Commercial Officer, and for one last time as Chief Medical Officer, Ivory Roberts. During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. Following prepared remarks, we will strive to get to everyone's questions. Now, I will turn the call over to Kyle.

Thanks, Todd. Good afternoon, everyone. Nurocrin has never been in a stronger position as we maintain an enterprise-wide focus on execution and evolution. Even with external factors continuing to create market volatility, We remain focused on controlling what we can, executing with discipline to meaningfully deliver for both patients and shareholders. The first quarter reflected strong execution across both of our brands, with record new patient starts for Ingresa and encouraging early adoption of Chronicity. With reformed guidance for Ingresa and solid momentum heading into Q2, combined with an early but promising launch trajectory for Chronicity, We are well positioned to drive both near and long-term revenue growth as we evolve from a single blockbuster to a multiple blockbuster neuroscience company. Amazing to see the efforts from our commercial and medical teams this quarter. Well done. On the R&D front, our portfolio continues to advance meaningfully. We are encouraged by the progression of Osa Vampator and MBI 568 into Phase III registrational studies. The strong magnitude of effect demonstrated in both programs, Phase II proof-of-concept studies, gives us confidence in continued investment. We are on track for expanding our muscarinic portfolio into new Phase II studies later this year. This includes MBI-568 into bipolar mania and MBI-570, our dual M1-M4 agonist, into schizophrenia. From a leadership perspective, we are thrilled to welcome Dr. Sanjay Keswani as our incoming chief medical officer in June. Dr. Irie Roberts, our current CMO, will transition into a strategic advisory role where her expertise will continue to shape key programs. In closing and reflecting on the quarter, I'm extremely proud of our team and progress. Our growing diversified revenue base, expanding pipeline, and strong balance sheet position us well to continue building on our momentum as a leading global neuroscience company. With that, I'll turn the call over to Matt.